



Congress Presidents

Axel Hauschild, Kiel, Germany Claus Garbe, Tuebingen, Germany

2025 in Hamburg

15th European Post-Chicago Melanoma/Skin Cancer Meeting

Hamburg | Germany Radisson Blu Hotel

european-post-chicago-meeting.org

June 26th-27th 2025



CONTENT

	>> WELCOME MESSAGE	03
	>> PROGRAM AT A GLANCE	06
	>> PROGRAM Thursday, June 26 th , 2025 Friday, June 27 th , 2025	06
	>> CONGRESS FACULTY	14
>>	SATELLITE SYMPOSIA OVERVIEW	18
	>> FLOOR PLAN	20
	>> GENERAL INFORMATION	22
	>> SPONSORS	24

WELCOME MESSAGE

Dear colleagues and friends,

We are excited to extend our warmest invitation to you for the upcoming Interdisciplinary Global Conference on News in Melanoma/Skin Cancer "European Post Chicago Meeting" in 2025. After many successful years in Munich, we are thrilled to announce that our event will be moving to the vibrant city of Hamburg, Germany.

Since our first meeting in 2011, the Post-Chicago Meeting on Melanoma/Skin Cancer has grown into a key event, with the 2024 edition drawing over 470 attendees on-site and 300 more virtually. This conference has always offered a comprehensive and interactive experience, providing deep insights into the latest advancements in melanoma diagnostics and therapy, while fostering direct communication with the world's leading experts.

Our move to Hamburg opens a new chapter for the conference. In this dynamic and historic city, we will continue our tradition of lively interaction among clinicians, researchers, and industry representatives. The 2025 conference will feature international key opinion leaders who will share cutting-edge research, present the latest clinical trial results, and engage in stimulating discussions on emerging therapies.

We look forward to welcoming you to Hamburg, where you will not only gain valuable scientific knowledge but also have the opportunity to connect with peers in a warm and familiar setting.

Join us in Hamburg for what promises to be another remarkable event!

Best regards,

Axel Hauschild, MD Congress President

1 beef Councelle

Claus Garbe, MD Congress President

PROGRAM AT A GLANCE

THURSDAY, JUNE 26th, 2025

	NEW YORK	SYDNEY
8:00	Opening of the conference	
	SYMPOSIUM I My personal highlights at ASCO 2025	
9:00		
	KEYNOTE LECTURE I	
10:00	SATELLITE SYMPOSIUM I	
	BREAK	
11:00	SATELLITE SYMPOSIUM II	
12:00	SYMPOSIUM II Attacking tumor cells	
13:00		
	BREAK	
14:00	SATELLITE SYMPOSIUM III	
15:00	SYMPOSIUM III Prognostic and predictive biomarkers	PARALLEL SYMPOSIUM I Registry data and studies: Update 2025
16:00	BREAK SYMPOSIUM IV Neoadjuvant/perioperative treatment for skin cancer	
17:00	SYMPOSIUM V Adverse event management for ICI	PARALLEL SYMPOSIUM II Cutaneous T-cell lymphoma (CTCL)
18:00		
10.00		

	NEW YORK	SYDNEY
8:00	SYMPOSIUM VI Adjuvant treatment of melanoma	PARALLEL SYMPOSIUM III Complex melanoma cases
9:00	SYMPOSIUM VII Whats new in guidelines and studies for	PARALLEL SYMPOSIUM IV Complex non-melanoma cases
10:00	SYMPOSIUM VIII ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas	
11:00	SATELLITE SYMPOSIUM IV	
	BREAK	
12:00	KEYNOTE LECTURE II	
	KEYNOTE LECTURE III	
13:00	LUNCH SATELLITE SYMPOSIUM V	
	SATELLITE SYMPOSIUM VI	
14:00	BREAK	
	SYMPOSIUM IX Is adjuvant treatment for melanoma dead?	
15:00	SYMPOSIUM X Melanoma survivorship	
	CLOSING REMARKS	
16:00		
17:00		
18:00		
19:00		

THURSDAY, JUNE 26th, 2025

08:00 OPENING OF THE CONFERENCE

NEW YORK CLAUS GARBE, TUEBINGEN, GERMANY

08:10–09:30 SYMPOSIUM I

My personal highlights at ASCO 2025

CHAIRPERSONS: MERRICK I. ROSS, HOUSTON, USA JOSEP MALVEHY, BARCELONA, SPAIN

08:10-08:45 ...in melanoma

Sapna Patel, Denver, USA

08:50-09:25 ... in non-melanoma skin cancer

Céleste Lebbé, Paris, France

09:30-10:00 KEYNOTE LECTURE I

NEW YORK CHAIRPERSON: CAROLINE ROBERT, PARIS, FRANCE

Cellular Therapies for melanoma

John Haanen, Amsterdam, Netherlands

10:00–10:45 SATELLITE SYMPOSIUM I

NEW YORK

10:45-11:00 BREAK

NEW YORK

11:00–12:00 SATELLITE SYMPOSIUM II

NEW YORK

12:00–13:00 SYMPOSIUM II

NEW YORK Attacking tumor cells

CHAIRPERSONS: JOHN HAANEN, AMSTERDAM, NETHERLANDS OLIVIER MICHIELIN, GENEVA, SWITZERLAND

12:00–12:15 How vaccines work

Olivier Michielin, Geneva, Switzerland

12:20–12:35 T cell engagers

Dirk Schadendorf, Essen, Germany

12:40–12:55 How to increase T cell fitness to improve immunotherapy? Caroline Robert, Paris, France

THURSDAY, JUNE 26th, 2025

13:00-14:00 BREAK

NEW YORK

14:00–15:00 SATELLITE SYMPOSIUM III

NEW YORK

15:00–16:00 SYMPOSIUM III

NEW YORK Prognostic and predictive biomarkers

CHAIRPERSONS: DIRK SCHADENDORF, ESSEN, GERMANY CHRISTOPH HOELLER, VIENNA, AUSTRIA

15:00–15:15 Gene Expression Profiling for melanoma primaries

Teresa Amaral, Tuebingen, Germany

15:15–15:30 Nomograms for stage II-IV melanoma Alexander van Akkooi, Sydney, Australia

15:30–15:45 Liquid biopsy for melanoma: ready for primetime? Christoffer Gebhardt, Hamburg, Germany

15:45-16:00 Discussion

15:00-17:00 PARALLEL SYMPOSIUM I

Registry data and studies: Update 2025

CHAIRPERSONS: LIDIJA KANDOLF, BELGRADE, SERBIA PETER MOHR, BUXTEHUDE

15:00–15:15 Real-world data: BCC studies

Josep Malvehy, Barcelona, Spain

15:15–15:30 Real-world data: SCC studies

Ulrike Leiter-Stoeppke, Tuebingen, Germany

15:30–15:45 Real-world data: rare cancers **Céleste Lebbé, Paris, France**

15:45–16:00 Real-world data: adjuvant melanoma studies

Eva Ellebaek Steensgaard, Copenhagen, Denmark

16:00–16:15 Real-world data: metastatic melanoma studies Michael Weichenthal, Kiel, Germany

16:15–16:30 SERIO registry update

Lucie Heinzerling, Munich, Germany

16:30–16:45 Access to medicines for melanoma in Europe Lidija Kandolf, Belgrade, Serbia

16:45-17:00 Discussion

THURSDAY, JUNE 26th, 2025

16:00–16:15 BREAK

16:15–17:15 SYMPOSIUM IV

NEW YORK

Neoadjuvant/perioperative treatment for skin cancer

CHAIRPERSONS: CHRISTIAN BLANK, AMSTERDAM, NETHERLANDS ALEXANDER VAN AKKOOI, SYDNEY, AUSTRALIA

16:15–16:30 ICI combinations for melanoma

Christian Blank, Amsterdam, Netherlands

16:35–16:50 Perioperative treatment for melanoma Merrick I. Ross, Houston, USA

16:55–17:10 Neoadjuvant treatment for NMSC

Jessica Hassel, Heidelberg, Germany

17:15 – 18:15

SYMPOSIUM V

NEW YORK

Adverse event management for ICI

CHAIRPERSONS: JESSICA HASSEL, HEIDELBERG, GERMANY LISA ZIMMER, ESSEN, GERMANY

17:15–17:30 What drives autoimmune adverse events? Lukas Flatz, Tuebingen, Germany

17:35–17:50 Systemic corticosteroids – friend or foe? **Helen Gogas, Athens, Greece**

17:55–18:10 ICI in preexisting autoimmune diseases Ralf Gutzmer, Minden, Germany

17:00-18:00

PARALLEL SYMPOSIUM II
Cutaneous T-cell lymphoma (CTCL)

SYDNEY

CHAIRPERSONS: CHALID ASSAF, KREFELD, GERMANY EMMANUELLA GUENOVA, LINZ, SWITZERLAND

17:15–17:30 Medical needs in CTCL

Pietro Quaglino, Turin, Italy

17:35–17:50 First-line treatment: standards and trials **Emmanuella Guenova, Linz, Switzerland**

17:55–18:10 Later-line treatment: standards and trials Chalid Assaf, Krefeld, Germany

08:00-09:00

SYMPOSIUM VI

NEW YORK

Adjuvant treatment of melanoma

CHAIRPERSONS: HELEN GOGAS, ATHENS, GREECE RALF GUTZMER, MINDEN, GERMANY

08:00–08:15 Which benefit justifies adjuvant treatment in stage II/III (NNT, number needed to treat)

Alexander Eggermont, Utrecht, Netherlands

08:20–08:35 However, adjuvant treatment goes along with adverse events (NNH, number needed to harm)

Elisabeth Livingstone, Essen, Germany

08:40–08:55 Are patients with acral melanomas good candidates for adjuvant treatment?

Paul Nathan, Northwood, United Kingdom

08:00-09:00

PARALLEL SYMPOSIUM III

SYDNEY

Complex melanoma cases

CHAIRPERSONS: IMKE VON WASIELEWSKI, HANNOVER, GERMANY ZELJKO MIJUSKOVIC, BELGRADE, SERBIA LAURA SUSOK, DORTMUND, GERMANY ULRIKE LEITER-STOEPPKE, TUEBINGEN, GERMANY

08:00-08:15 Case 1

Zeljko Mijuskovic, Belgrade, Serbia

08:15-08:30 Case 2

Imke von Wasielewski, Hannover, Germany

08:30-08:45 Case 3

Laura Susok, Dortmund, Germany

08:45-09:00 Case 4

Ulrike Leiter-Stoeppke, Tuebingen, Germany

09:00-10:00

SYMPOSIUM VII

NEW YORK

Whats new in guidelines and studies for...

CHAIRPERSONS: KETTY PERIS, ROME, ITALY
VISHAL PATEL, WASHINGTON, USA

09:00–09:18 ... basal cell carcinoma Ketty Peris, Rome, Italy

09:18-09:36 ... squamous cell carcinoma

Vishal Patel, Washington, USA

09:36-09:54 ... other skin malignancies

Philippe Saiag, Paris, France

09:00-10:00

PARALLEL SYMPOSIUM IV

SYDNEY

Complex non-melanoma cases

CHAIRPERSONS: PETR ARENBERGER, PRAGUE, CZECH REPUBLIC ANA MARIA FORSEA, BUCHAREST, ROMANIA DAGMAR VON BUBNOFF, LUEBECK, GERMANY

09:00-09:20 Case 1

Petr Arenberger, Prague, Czech Republic

09:20-09:40 Case 2

Ana Maria Forsea, Bucharest, Romania

09:40-10:00 Case 3

Dagmar von Bubnoff, Luebeck, Germany

10:00–10:45

SYMPOSIUM VIII

NEW YORK

ImmTACs: novel bi-specific agents for metastatic uveal and cutaneous melanomas

CHAIRPERSON: AXEL HAUSCHILD, KIEL, GERMANY

10:00–10:15 Experiences from a high-volume ImmTAC center Christoffer Gebhardt, Hamburg, Germany

10:15–10:35 Tebentafusp, Brenetafusp and other ImmTACs not only for uveal melanomas

Paul Nathan, Northwood, United Kingdom

10:35-10:45 Discussion

10:45-11:30

SATELLITE SYMPOSIUM IV

NEW YORK

11:30-11:45

BRFAK

11:45–12:15

KEYNOTE LECTURE II

NEW YORK

CHAIRPERSON: PAUL NATHAN, NORTHWOOD, UNITED KINGDOM

Metastatic uveal melanoma – future perspectives

Josep Maria Piulats Rodriguez, Barcelona, Spain

12:15–12:45 KEYNOTE LECTURE III

NEW YORK CHAIRPERSON: DIRK SCHADENDORF, ESSEN, GERMANY

Diets for cancer patients: are they worthwhile?

Alpaslan Tasdogan, Essen, Germany

12:45–13:30 LUNCH SATELLITE SYMPOSIUM V

NEW YORK

13:30–14:00 SATELLITE SYMPOSIUM VI

NEW YORK

14:00–14:15 BREAK

14:15–15:05 SYMPOSIUM IX

NEW YORK

Is adjuvant treatment for melanoma dead?

CHAIRPERSONS: ALEXANDER EGGERMONT, UTRECHT, NETHERLANDS JAMES LARKIN, SUTTON, UNITED KINGDOM

14:15-14:30 Yes

Christian Blank, Amsterdam, Netherlands

14:30-14:45 No

Mario Mandala, Perugia, Italy

14:45-15:05 Panel Discussion

15:05–15:45 SYMPOSIUM X

NEW YORK Melanoma survivorship

CHAIRPERSONS: ELISABETH LIVINGSTONE, ESSEN, GERMANY

MERRICK I. ROSS, HOUSTON, USA

15:05–15:20 Melanoma survival steadily increases

Lisa Zimmer, Essen, Germany

15:25–15:40 Quality of life, complaints and needs

Andrea Forschner, Tuebingen, Germany

15:45 CLOSING REMARKS

NEW YORK AXEL HAUSCHILD, KIEL, GERMANY

CONGRESS FACULTY

A F

Teresa Amaral, MD

Senior Physician, Dermatology University Hospital Tuebingen Liebermeisterstraße 25 72076 Tuebingen, Germany

Petr Arenberger, MD

Professor of Dermatology Charles University Prague Šrobárova 50 100 34 Prague, Czech Republic

Chalid Assaf, MD

Head Physician, Dermatology Helios Klinikum Krefeld Lutherplatz 40 47805 Krefeld, Germany

B

Christian Blank, MD

Professor of Oncology Netherlands Cancer Institute Plesmanlaan 121 1066 CX Amsterdam, Netherlands

E

Alexander Eggermont, MD

General Director Princess Máxima Center for Pediatric Oncology Heidelberglaan 25 3584 CS Utrecht, Netherlands

Andrea Forschner, MD

Head of Melanoma Outpatient Clinic University Hospital Tuebingen Liebermeisterstraße 25 72076 Tuebingen, Germany

Ana Maria Forsea, MD

Professor of Dermatology Carol Davila University of Medicine Dionisie Lupu 37 Bucharest, Romania

Lukas Flatz, MD

Senior Physician, Dermatology University Hospital Tuebingen Liebermeisterstraße 25 72076 Tuebingen, Germany

G

Claus Garbe, MD

Eberhard Karls University University Hospital Tuebingen Liebermeisterstraße 25 72076 Tuebingen, Germany

Christoffer Gebhardt, MD

Professor of Dermatology University Medical Center Hamburg-Eppendorf Martinistraße 52 20246 Hamburg, Germany

Emmanuella Guenova, MD

Head, Clinical Department of Translational Immunodermatology Kepler University Hospital Linz University Hospital of Dermatology and Venerology Med Campus III., Krankenhausstraße 9 4021 Linz

Helen Gogas, MD

Professor of Medicine National and Kapodistrian University of Athens Panepistimiou 30 10679 Athens, Greece

Ralf Gutzmer, MD

Head Physician, Dermatology Johannes Wesling Klinikum Minden Hans-Nolte-Straße 1 32429 Minden, Germany

Н

John Haanen, MD

Head, Department of Medical Oncology Netherlands Cancer Institute Plesmanlaan 121 1066 CX Amsterdam, Netherlands

Jessica Hassel, MD

Head, Dermato-Oncology National Center for Tumor Diseases (NCT) Im Neuenheimer Feld 460 69120 Heidelberg, Germany

Axel Hauschild, MD

Professor of Dermatology University Hospital Schleswig-Holstein Arnold-Heller-Straße 3 24105 Kiel, Germany

Lucie Heinzerling, MD

Head, Dermato-Oncology LMU University Hospital Skin Cancer Center at CCC Munich Frauenlobstraße 9–11, 80337 Munich, Germany

Christoph Hoeller, MD

Department of Dermatology Medical University of Vienna Vienna, Austria

K

Lidija Kandolf, MD

Professor of Dermatology Clinical Center of Serbia Pasterova 2 11000 Belgrade, Serbia

James Larkin, MD

Head of The Royal Marsden Skin Unit The Royal Marsden/Institute of Cancer Research Downs Road, Sutton, Surrey, SM2 5PT United Kingdom

Celeste Lebbé, MD

Professor of Dermatology Hôpital Saint-Louis 1 Avenue Claude Vellefaux 75010 Paris, France

Ulrike Leiter-Stoeppke, MD

Head, Dermatology Department University Hospital Tuebingen Liebermeisterstraße 25 72076 Tuebingen, Germany

Elisabeth Livingstone, MD

Senior Physician, Dermatology University Hospital Essen Hufelandstraße 55 45147 Essen, Germany



Mario Mandalà, MD

Senior Researcher, Oncology University of Perugia Piazza Università 06123 Perugia, Italy

Josep Malvehy, MD

Director, Melanoma Unit Hospital Clínic de Barcelona Carrer de Villarroel, 170 08036 Barcelona, Spain

Olivier Michielin, MD

Head, Precision Medicine Geneva University Hospitals Rue Gabrielle-Perret-Gentil 4 1211 Geneva 14, Switzerland

Peter Mohr, MD

Chief Physician, Dermatology Elbe Klinikum Buxtehude Am Krankenhaus 1 21614 Buxtehude, Germany

N

Paul Nathan, MD

Consultant Oncologist Mount Vernon Cancer Centre Rickmansworth Rd Northwood HA6 2RN, United Kingdom

P

Sapna Patel, MD

Director, Melanoma Program University of Colorado Cancer Center 13001 E 17th PI, Aurora, CO 80045, USA

Vishal Patel, MD

Associate Professor of Dermatology at the George Washington University School of Medicine & Health Sciences
Associate Professor of Medicine (Oncology) at GW Cancer Center
George Washington Medical Faculty Associates 2150 Pennsylvania Avenue NW, 2nd Floor Washington, DC 20037, USA

Ketty Peris, MD

Director, Dermatology Università Cattolica del Sacro Cuore Largo Francesco Vito, 1 00168 Rome, Italy

0

Pietro Quaglino, MD

Associate Professor Dermatologic Clinic, Department of Medical Sciences, University of Turin, Corso Bramante 88 10126 Turin, Italy

R

Josep Maria Piulats Rodriguez, MD

Senior Researcher, Oncology Hospital Clínic de Barcelona Carrer de Villarroel, 170 08036 Barcelona, Spain

Caroline Robert, MD

Head, Dermatology Department Gustave Roussy 114 Rue Edouard Vaillant 94800 Villejuif, France

Merrick I. Ross, MD

University of Texas Department of Surgical Oncology, Division of Surgery Houston, USA



Dirk Schadendorf, MD

Director & Chair Department of Dermatology & Director, Comprehensive Cancer Center University Hospital Essen & Research Alliance Ruhr, Research Center One Health, University Duisburg-Essen Hufelandstraße 55 45147 Essen, Germany

Philippe Saiag, MD

Head, Dermatology Department Hôpital Ambroise-Paré 9 Avenue Charles de Gaulle, 92100 Boulogne-Billancourt, France

Laura Susok, MD

Director, Department of Dermatology Klinikum Dortmund Muensterstraße 240 44145 Dortmund, Germany

Т

Z

Alpaslan Tasdogan, MD

Professor of Dermatology and Tumor Metabolism University Hospital Essen Hufelandstraße 55 45147 Essen, Germany

Lisa Zimmer, MD

Senior Physician, Oncology University Hospital Essen Hufelandstraße 55 45147 Essen, Germany



Alexander van Akkooi, MD

Head, Melanoma and Skin Cancer Center Melanoma Institute Australia 40 Rocklands Rd North Sydney NSW 2060, Australia

Dagmar von Bubnoff, MD

Professor of Dermatology
Deputy Director of the Clinic
Head of the Allergy Department
Department of Allergology and Drug-Based Tumor
Therapy
University Medical Center Schleswig-Holstein
Clinic for Dermatology, Allergology, and Venereology
Ratzeburger Allee 160
23538 Luebeck, Germany

Imke von Wasielewski, MD

Head of the Skin Cancer Center Head of Dermato-Oncology Department of Dermatology, Allergology, and Venereology, Hannover Medical School Carl-Neuberg-Straße 1 30625 Hannover, Germany



Michael Weichenthal, MD

Professor of Dermatology University Hospital Schleswig-Holstein Arnold-Heller-Straße 3 24105 Kiel, Germany

SATELLITE SYMPOSIA OVERVIEW

THURSDAY, JUNE 26th, 2025

10:00–10:45	SATELLITE SYMPOSIUM I REPLIMUNE Gold Sponsor				
	Optimizing Treatment for Skin Cancers in Immunocompromised Patients				
	CHAIR: AXEL HAUSCHILD, KIEL, GERMANY				
	10:00–10:05 Introduction Axel Hauschild, Kiel, Germany				
	10:05–10:20 Skin Cancer Risks in the Post-Transplant Setting Alexander van Akkooi, Sydney, Australia				

10:20–10:35 Treatment Paradigms for Post-Transplantation Cutaneous Malignancies Christoffer Gebhardt, Hamburg, Germany

10:35–10:45 Discussion, Q&A and Conclusions

Axel Hauschild, Kiel, Germany

11:00-12:00 SATELLITE SYMPOSIUM II

REGENERON Platinum Sponsor

Advancing Immunotherapy in Patients with Cutaneous Squamous Cell Carcinoma (CSCC) at Risk of Recurrence

CHAIR: AXEL HAUSCHILD, KIEL, GERMANY

Topics:

- Defining high-risk features in patients with CSCC at risk of recurrence
- Evaluating adjuvant immunotherapy in patients with high-risk CSCC
- Exploring immunotherapy approaches in neoadjuvant, adjuvant, and perioperative settings

Christoffer Gebhardt, Hamburg, Germany Vishal Patel, Washington, USA

14:00-15:00 SATELLITE SYMPOSIUM III

MSD Platinum Sponsor

Navigating early-stage melanoma:

Evolution of adjuvant treatment outcomes and future directions

14:00–14:05 Welcome and opening remarks
 Axel Hauschild, Kiel, Germany
 14:05–14:25 Treatment evolution to prevent recurrence in early-stage melanoma:
 Time to look back/ahead 5-min. Q&A
 Dirk Schadendorf, Essen, Germany

14:25–14:40 Clinical cases and panel discussion Merrick Ross, Houston, USA

14:40–14:55 Integrating novel treatment modalities in the adjuvant setting 5-min. Q&A Christoffer Gebhardt, Hamburg, Germany

14:55–15:00 Closing remarks

Axel Hauschild, Kiel, Germany

10:45-11:30 SATELLITE SYMPOSIUM IV

BMS Gold Sponsor

Evolving Frontiers in Melanoma 2025:A Visionary Panel on Progress and Promise

CHAIR AND EXPERT PENALIST: AXEL HAUSCHILD, KIEL, GERMANY EXPERT PENALIST: CHRISTOPH HOELLER, VIENNA, AUSTRIA

JAMES LARKIN, SUTTON, UNITED KINGDOM

12:45-13:30 LUNCH SATELLITE SYMPOSIUM V

SunPharma Gold Sponsor

Neoadjuvant therapy for resectable stage III melanoma in 2025: Current Evidence

CHAIR: AXEL HAUSCHILD, KIEL, GERMANY

Welcome and Introduction

Axel Hauschild, Kiel, Germany

Theoretical part:

Current published evidence on the neoadjuvant approach in stage III melanoma

Axel Hauschild, Kiel, Germany

Clinical part:

Clinical Case

Paul Nathan, Northwood, United Kingdom

Clinical Case

Alexander Van Akkooi, Sydney, Australia

Discussion

All

Closure

Axel Hauschild, Kiel, Germany

13:30-14:00 SATELLITE SYMPOSIUM VI

MERCK

SPEAKER: AXEL HAUSCHILD, KIEL, GERMANY


Real-World Perspectives: Outcomes and Clinical

Practice Lessons from Treating Advanced Merkel Cell Carcinoma

FLOOR PLAN

RADISSON BLU HOTEL HAMBURG

ERDGESCHOSS/GROUND FLOOR



*Los Angeles, Chicago , Dallas & Philadelphia = New York

GENERAL INFORMATION

Cancellation Policy

Cancellations must be received in writing by May 11th, 2025. No refunds will be granted after that date. To cancel a registration, please send an email to info@medconcept.org and include "European Post-Chicago Meeting 2024 Cancellation" in the subject line. A processing fee of 30 euros will be deducted from each canceled registration.

Substitutions (new ticket holders must come from the same institution) are possible and must be received in writing by June 16th, 2025. To substitute a registration please send an email including the name of the original registrant and the name of the person substituting to info@medconcept.org and include "European Post-Chicago Meeting 2025 Substitution" in the subject line.

The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the meeting be hindered or prevented by unexpected, political or economic events or generally by force or should the non-appearance of speakers or other reasons need program changes. With registration, the participant accepts this proviso.

CME Credits

An application for CME accreditation will be made.

Congress Date

June 26th-June 27th, 2025

Congress Organization



Gesellschaft für medizinische Projekte mbH Friedenstraße 58, 15366 Neuenhagen bei Berlin, Germany info@medconcept.org | www.medconcept.org Phone +49 (0)3342 42689-30 | Fax +49 (0)3342 42689-40

Congress Venue

Radisson Blu Hotel Hamburg Congresspl. 2, 20355 Hamburg, Germany

Phone: +49 (0)40 3502 3100 | E-Mail: info.hamburg@radissonblu.com

Exhibition

A commercial exhibition will be held at the congress venue, close to the main rooms.

Exhibition Opening Hours

Thursday, June 26th, 2025 07:30–18:30 Friday, June 27th, 2025 07:30–18:00

Insurance

The Organizer does not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements with respect to health and travel insurance.

Language and Translation

The official language of the meeting will be English. Simultaneous translation will not be provided.

Registration and Information Desk

The registration desk is situated at the ground floor of the Radisson Blu Hotel to the right of the reception and in front of the meeting area entrance.

Registration Desk Opening Hours

Thursday, June 26th, 2025 07:00–19:00 Friday, June 27th, 2025 07:30–18:00

Registration Fees

Virtual packages and on-demand service is included in all ticket categories.

	Presence Tickets			Virtual Tickets	
	Early Bird until May 1 st , 2025	Regular Fee until June 16 th , 2025	Late		
Full Delegate Ticket	400 euros	500 euros	600 euros	400 euros	
EADO Members	300 euros	400 euros	500 euros	300 euros	
Students/Nurses Ticket*	150 euros	200 euros	250 euros	150 euros	
Eastern European Countries*	150 euros	200 euros	250 euros	150 euros	
Residents*	150 euros	200 euros	250 euros	150 euros	

^{*}Please upload proof of university or clinic for students/nurse ticket, and proof of residence in a european eastern country for reduced tickets of this category, during registration process.

SPONSORS

PLATINUM





GOLD









SILVER



BRONZE

IMMUNOCORE

EXHIBITORS AN SPONSORS



15th European Post-Chicago Melanoma/Skin Cancer Meeting Industry Satellite Symposium

Advancing Immunotherapy in Patients with Cutaneous Squamous Cell Carcinoma (CSCC) at Risk of Recurrence

Thursday, 26 June 2025 11:00-12:00 CEST

Room: New York Radisson Blu Hotel, Hamburg

Topics

- Defining high-risk features in patients with CSCC at risk of recurrence
- Evaluating adjuvant immunotherapy in patients with high-risk CSCC
- Exploring immunotherapy approaches in neoadjuvant, adjuvant, and perioperative settings



This symposium is intended for healthcare professionals only. It has been organised and fully sponsored by Regeneron Pharmaceuticals Inc.



Dermato-Onkologie UPDATE 2026

20.-22.2.2026
Mercure Hotel MOA Berlin
HYBRID MEETING





22 EADO CONGRESS

April 23th-25th, 2026
PRAGUE, CZECH REPUBLIC
O2 UNIVERSUM

SAVE THE DATE

ON-SITE CONGRESS WITH ADDITIONAL VIRTUAL ACCESS WWW.EADO2026.COM





Apply now for EADO Certification 2025



EADO Certification: Medical Tumour Therapy in Dermato-Oncology

June 28, 2025

Radisson Blu Hotel Hamburg, Germany

APPLICATION DEADLINE MAY 15, 2025

VISIT EADO.ORG







Data-Driven Oncology

Empowering biopharmaceutical innovation with comprehensive, real-world data-driven insights

Our Services

- Study design (Protocols, electronic case report forms (eCRFs), questionnaires, surveys)
- Definition of centers for recruitment and management
- Medical-scientific consulting
- Comprehensive study management
- Handling of regulatory submissions and approval processes
- IT infrastructure (electronic data capture, database services)
- Data collection and management
- Planning of biostatistical analyses and biostatistical evaluation
- Final reports, publications, medical writing
- Adverse event (AE)/Serious adverse event (SAE)/Adverse drug reaction (ADR)/Serious adverse drug reaction (SADR) management

HE

Friedenstraße 58 15366 Neuenhagen bei Berlin

Telefon: +49 (0) 3342 42689-50 Fax: +49 (0) 3342 42689-60 info@heraclin.de www.heraclin.de





MedConcept Gesellschaft für medizinische Projekte mbH Friedenstraße 58, 15366 Neuenhagen



+49 3342 42689-30



info@medconcept.org



www.medconcept.org



Experience since 1997

Congress On-Demand

All approved lectures from the EVENT will be available on the On-Demand platform from July 1, 2025 until September 30, 2025.

The on-demand service is available to all registered attendees (F2F and virtual).

THE AREA IS PASSWORD PROTECTED

Access to the On-Demand area is granted using the same login credentials as for the virtual platform.

NOTES

IMPORTANT INFORMATION

Internet Connection

Free Wi-Fi service will be available to all delegates within the Radisson Blu Hotel.

Certificate of Attendance:

All registered attendees will receive a certificate of attendance within 10 days after the meeting via e-mail and after completing an evaluation survey.

Please note! If you need to change your contact e-mail address, please come to the registration desk.

Name Badges

Name badges must be worn visibly at all times during the meeting and in the exhibition area.

Daily Scan

To receive your daily CME credits please remember to scan yourself once a day at the registration desk. German participants must also register in the barcode list of the Bayarian Medical Association.

TED/Polling

Please scan the QR code with your mobile device or visit **www.slido.com** and enter the event code to participate in the polling.